Leave a message
HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

5th Edition of International Conference on Tissue Engineering and Regenerative Medicine

September 18-20 | London, UK

September 18 -20, 2025 | London, UK
TERMC 2025

Evaluating interleukin-2 and its receptors as indicators of acute renal graft rejection

Athina Gompou, Speaker at Regenerative Medicine Conferences
IASO Thessaly, Greece
Title : Evaluating interleukin-2 and its receptors as indicators of acute renal graft rejection

Abstract:

Introduction: Interleukin-2 (IL-2) is a cytokine that exerts its actions via binding to a variety of interleukin-2 receptors (IL-2R), thereby stimulating T-cell response. Acute renal graft rejection (AR) is known to be mediated by CD8+ T-cells, through the IL-2 pathway. The aim of this study was to determine whether IL-2 and IL-2R could work as prognostic biomarkers of AR.

Methods: IL-2, IL-2R and Cystatin-C levels were measured in the serum of 50 patients who underwent a kidney transplant, once pre-operatively and at four different time points post-operatively (second, sixth, 14th day and third month). Of the total number of patients, ultimately 10 (20%) had an episode of AR.

Results: No statistically significant difference in IL-2 levels was found between those who experienced AR and those who did not, at any of the studied time points. On the other hand, measurement of IL-2R levels on the sixth and 14th day post-operatively showed that people with AR had a statistically significant increase in its value compared to patients who did not have an AR episode (p=0.027 and p=0.019, respectively). In addition, comparing the values of IL-2R with that of Cystatin-C in different time periods, it was found that there is a significant positive linear correlation on the second and sixth postoperative day between the values of the associated parameters (r=0.280, p=0.049 and r=0.372, p=0.008 respectively).

Conclusion: The measurement of IL-2R from the sixth to 14th postoperative day could be used as a reliable prognostic biomarker of AR, however additional studies and standardised diagnostic thresholds are required before the routine clinical application is feasible.

Biography:

Athina Gompou is the director of the Department of Nephrology and Renal Dialysis at IASO Thessaly, Larissa, Greece. She was a resident and after that a specialized doctor in the Department of Nephrology, Transplantation Unit in Laiko General Hospital of Athens, the capital of Greece. Her approach with new patients starts with kindness and her knowledge about nephrology are huge.

Watsapp
a